Italy Pharmaceuticals and Healthcare Report Q2 2016

60 pages report Published in
Pharmaceuticals
Publisher: Business Monitor International

arrowFor This Report

BMI View: The economic recovery that began in 2015 after a three year recession will gather momentum
in 2016, although the recovery will remain relatively tepid. Employment will increase, as will consumer
confidence and this will provide a boost to the retail sector. However, because the recovery will be
relatively tepid, we believe that essential spending will increase more rapidly than non-essential spending.
Low inflation and low interest rates will also help to boost retail spending in 2016.
Key Views & Developments
? The economic recovery that began in 2015, when the Italian economy returned to positive growth after
three years of recession, will gather momentum in 2016 and we expect headline economic growth to
register 1.2%, up from 0.8% in 2015.

Table of Contents

BMI Industry View 7
SWOT 9
Industry Forecast 11
Headline Retail Forecast 11
Table: Total Household Spending (Italy 2013-2020) 12
Table: Retail Sector Spending, % Of Total (Italy 2013-2020) 12
Table: Retail Sector Spending, % of GDP (Italy 2013-2020) 14
Table: Headline Retail Sector Spending (Italy 2013-2020) 16
Retail Sector Forecast 17
Food, Drink And Tobacco Spending 19
Table: Food, Drink & Tobacco Spending (Italy 2013-2020) 19
Clothing And Footwear Spending 20
Table: Clothing & Footwear Spending (Italy 2013-2020) 20
Household Goods Spending 21
Table: Household Goods Spending (Italy 2013-2020) 21
Table: Consumer Electronics Spending (Italy 2013-2020) 23
Personal Care Spending 23
Table: Personal Care Spending (Italy 2013-2020) 24
Household Numbers and Income Forecast 24
Table: Household Income Data (Italy 2013-2020) 26
Demographic Forecast 28
Table: Total Population (Italy 2013-2020) 29
Table: Population: Babies (Italy 2013-2020) 30
Table: Population: Young Children (Italy 2013-2020) 30
Table: Population: Children (Italy 2013-2020) 30
Table: Population: Young Teens and Older Children (Italy 2013-2020) 31
Table: Population: Young People (Italy 2013-2020) 31
Table: Population: Older Teenagers (Italy 2013-2020) 31
Table: Population: 21yrs + (Italy 2013-2020) 32
Table: Population: Young Adults (Italy 2013-2020) 32
Table: Population: Middle Aged (Italy 2013-2020) 32
Table: Population: Urban (Italy 2013-2020) 33
Industry Risk Reward Ratings 34
Developed States Risk/Reward Index 34
Table: Developed States Retail Risk/Reward Index, Q216 34
Italy Risk/Reward Index 35
Rewards 35
Risks 36
Market Overview 38
Competitive Landscape 45
Table: Major Clothing And Footwear Retailers 45
Table: Household Goods Retailers 45
Table: Electronics Retailers 46
Table: Major E-commerce Retailers 46
Table: Pharmacies Retailers 46
Glossary 47
Methodology 54
Industry Forecast Methodology 54
Sources 57
Risk/Reward Index Methodology 57
Table: Retail Risk/Reward Index Indicators 58
Table: Weighting Of Indicators 60

List of Tables

Table: Total Household Spending (Italy 2013-2020)
Table: Retail Sector Spending, % Of Total (Italy 2013-2020)
Table: Retail Sector Spending, % of GDP (Italy 2013-2020)
Table: Headline Retail Sector Spending (Italy 2013-2020)
Table: Food, Drink & Tobacco Spending (Italy 2013-2020)
Table: Clothing & Footwear Spending (Italy 2013-2020)
Table: Household Goods Spending (Italy 2013-2020)
Table: Consumer Electronics Spending (Italy 2013-2020)
Table: Personal Care Spending (Italy 2013-2020)
Table: Household Income Data (Italy 2013-2020)
Table: Total Population (Italy 2013-2020)
Table: Population: Babies (Italy 2013-2020)
Table: Population: Young Children (Italy 2013-2020)
Table: Population: Children (Italy 2013-2020)
Table: Population: Young Teens and Older Children (Italy 2013-2020)
Table: Population: Young People (Italy 2013-2020)
Table: Population: Older Teenagers (Italy 2013-2020)
Table: Population: 21yrs + (Italy 2013-2020)
Table: Population: Young Adults (Italy 2013-2020)
Table: Population: Middle Aged (Italy 2013-2020)
Table: Population: Urban (Italy 2013-2020)
Table: Developed States Retail Risk/Reward Index, Q216
Table: Major Clothing And Footwear Retailers
Table: Household Goods Retailers
Table: Electronics Retailers
Table: Major E-commerce Retailers
Table: Pharmacies Retailers
Table: Retail Risk/Reward Index Indicators
Table: Weighting Of Indicators

Related Reports

  • Netherlands Pharmaceuticals and Healthcare Report Q2 2016BMI View: The value of the Dutch pharmaceutical market will see yet another year of contraction in 2016, although we expect a return to growth - albeit marginal - in the following years. A relatively low risk environment and a well establish healthcare sector, thanks to high government expenditure, coupled with an aging population will aid in the recovery of the market. However, the country's ever-growing healthcare bills will increase the likelihood of the government implementing […]
  • Russia Pharmaceuticals and Healthcare Report Q2 2016BMI View: Russia's healthcare market is in a precarious position due to a severe lack of funding and an escalating burden of disease. The country's economic recession will see further pressure placed on the population for provision of care. Amendments to Russia's pharmaceutical legislation will, however, favour domestically-produced medicines over foreign drugmakers and multinational drugmakers will be pressured to establish a domestic manufacturing presence to comply to related new […]
  • Greece Pharmaceuticals and Healthcare Report Q4 2015BMI View: Despite the parlous state of the Greek economy and the imposition of emergency capital controls, drugmakers will maintain their commitment to the country's pharmaceutical market and ensure continuity of supply. Authorities will further restrict parallel exports to prevent medicine shortages. However, given that we expect Greece to return to a recession in 2015 and government revenues to fall, liquidity issues within the pharmaceutical supply chain will persist and debts […]
  • Russia Pharmaceuticals and Healthcare Report Q1 2016BMI View: Russia's healthcare and pharmaceutical markets are in a precarious position due to the country's economic recession. Healthcare in the country remains desperately in need of additional funding, and amendments to Russia's pharmaceutical legislation will hinder market access for drugmakers due to complex medicine registration laws and increased governmental influence on pricing. With significant challenges facing both sectors, we see a reduction in attractiveness of the […]
  • China Pharmaceuticals and Healthcare Report Q2 2016BMI View: The merger of China's new rural cooperative medical scheme with its urban residents basic medical insurance scheme will reshape the country's healthcare landscape. This will have important ramifications for the pharmaceutical industry as reimbursement models shift correspondingly. While this perpetuates the shifting dynamics within China in 2016, the long-term impacts are positive - expanding the depth of coverage to more patients and improving the system's financial […]